Rhode Island

In Review: PCMA submitted testimony in support of a House Corporations amendment bill to limit pharmacy audits. A PCMA member provided this amendment to the Speaker’s office. The Senate Health and Human Services Committee held a hearing on various PBM-related

In Review: PCMA submitted written testimony on SB 477, which would require copay coupons to be applied to a patient’s deductible. The Senate Health and Human Services Committee heard the bill where it will be held for further study. If you have

In Review: The legislature adjourned Thursday night, and PCMA mitigated a white bagging bill by requiring the hospital to match the PBM specialty pharmacy price. The remaining 21 bills PCMA testified on or submitted written testimony were defeated. If you

In Review: The House Finance Committee held a hearing on H 7897 limiting prior authorizations and step therapy for serious mental illness. PCMA submitted written testimony in opposition to the bill. The bill was held for further study. PCMA participated

Up Next: PCMA will participate in a stakeholder meeting organized by Speaker Joe Shekarchi’s (D) policy staffer on Monday, April 29. PCMA will be prepared to discuss our concerns with H 7365, which was previously held for further study. If

In Review: The House Corporations Committee held a hearing on H 7720, an affiliate pharmacy bill, and H 8041, a bill requiring copay coupons to be applied to a patient’s deductible. PCMA submitted written testimony in opposition to both bills

In Review: The Senate Health and Human Services Committee held hearings on S 2069, imposing a copay cap of $25 on asthma inhalers, and S 2177, which would no longer allow utilization management to treat alcohol or opioid use disorder.

In Review: PCMA testified in the House Health & Human Services Committee on HB 7365, a white bagging bill. PCMA also submitted written testimony on HB 7518 (inhaler copay cap), HB 7822 (step therapy mandates), and HB 7879 (no longer

In Review: The Senate Health and Human Services Committee held a hearing on various PBM-related bills. PCMA submitted testimony on a ban on prior authorization and step therapy for prescriptions for any HIV prevention drug, reference pricing, a ban on

In Review: PCMA submitted written testimony on various PBM bills in the House Committee on Health and Human Services. The bills include: a reference pricing bill, a ban on utilization management for treating alcohol or opioid use disorder, and a